

RECORDATI: UPDATE ON THE EXECUTION OF THE SHARE BUY-BACK PROGRAM

Milan, 2nd November 2022 – Within the Recordati’s share buy-back program communicated to the market and initiated on 20th June 2022, as per authorization granted by the Shareholders’ Meeting held on 29th April 2022, with the object of the servicing of current and future stock option plans in favour of Recordati Group’s management or share-based incentive plans that should be approved by the Company in the future, the Company communicates the following purchase transactions of Recordati shares pursuant to art. 2, paragraph 3, of the EU Delegated Regulation 2016/1052/UE, on the basis of the information provided by UBS Europe SE as intermediary in charge of executing, in full independency, the share buy-back program on behalf of the Company.

Aggregate details of daily transactions made from 24th October to 28th October 2022 in Recordati ordinary shares (ISIN IT0003828271) are as follows:

SUMMARY OF PURCHASE TRANSACTIONS FROM 24 TH OCTOBER 2022 TO 28 TH OCTOBER 2022				
Date	Type of Transaction	Quantity	Weighted average price (Euro)	Exchange
24/10/2022	Purchase	129	36.0400	MTA
28/10/2022	Purchase	1,926	37.4050	MTA
TOTAL		2,055	37.3193	

The details of all the purchase transactions carried out in the period indicated above are reported in the following pages.

On 28th October 2022, the Company held no. 3,792,271 treasury shares which amount to 1.813% of the current share capital.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2021 was € 1,580.1 million, operating income was € 490.2 million and net income was € 386.0 million.

For further information:

Recordati website: www.recordati.it

Investor Relations

Federica De Medici
(39) 02 48787146

e-mail: investorelations@recordati.it

Investor Relations

Lucia Abbatantuoni
(39) 02 48787213

e-mail: investorelations@recordati.it

Media Relations

Brunswick: Barbara Scalchi / Andrea Mormandi
(39) 02 9288 6200

e-mail: recordati@brunswickgroup.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1
20148 Milano, Italy
Ph. (39) 02 487871
Fax (39) 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l

Attachment:
Daily details of transactions

Trade Date	Trade Time (GMT)	Currency	Exchange	Trade Price	Quantity
24/10/2022	08:09:35	EUR	MTA	36,0400	129
28/10/2022	08:13:27	EUR	MTA	37,4100	131
28/10/2022	08:27:32	EUR	MTA	37,1200	145
28/10/2022	08:27:32	EUR	MTA	37,1200	8
28/10/2022	08:51:08	EUR	MTA	37,3800	40
28/10/2022	08:51:08	EUR	MTA	37,3800	91
28/10/2022	08:59:55	EUR	MTA	37,4300	156
28/10/2022	09:01:06	EUR	MTA	37,4600	126
28/10/2022	09:03:03	EUR	MTA	37,4600	141
28/10/2022	09:03:03	EUR	MTA	37,4600	140
28/10/2022	09:11:19	EUR	MTA	37,5100	148
28/10/2022	09:49:43	EUR	MTA	37,4400	124
28/10/2022	10:52:09	EUR	MTA	37,3500	135
28/10/2022	11:06:35	EUR	MTA	37,3400	244
28/10/2022	11:06:35	EUR	MTA	37,3300	147
28/10/2022	11:06:35	EUR	MTA	37,3300	3
28/10/2022	12:31:52	EUR	MTA	37,6400	147